Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00063076 · ClinicalTrials.gov registry record · Phase 2
Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT00063076: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00063076 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 46 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00063076, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the most effective dose of Targretin® (bexarotene) Gel 1% that can be given to patients as a treatment for alopecia areata. The safety and tolerability of this drug will also be studied. Objectives: 1. Determine the safety and tolerability of Targretin® Gel 1% in the treatment of patients with alopecia areata. 2. Determine the efficacy of Targretin® Gel 1% in the treatment of patients with alopecia areata.
Interventions
- DRUG Targretin Gel 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2003-05 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00063076
The ClinicalTrials.gov registry entry for NCT00063076 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Targretin Gel 1% is the first listed.
NCT00063076 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00063076 about?
NCT00063076 is a clinical study titled "Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata". The goal of this clinical research study is to find the most effective dose of Targretin® (bexarotene) Gel 1% that can be given to patients as a treatment for alopecia areata. The safety and tolerability of this drug will also be studied. Objectives: 1. Determine the safety and tolerability of Tar...
What is the current status of trial NCT00063076?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2003-05. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00063076?
The interventions under investigation include: Targretin Gel 1% (DRUG).
Who is sponsoring clinical trial NCT00063076?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.